Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

Press Release

Advocates Applaud Launch of World's First Phase II Rectal Microbicide Study

Trial Design Significantly Enhanced by Strong Community Input

October 2, 2013

Advocates Applaud Launch of World's First Phase II Rectal Microbicide Study

IRMA applauds the launch of the world's first-ever Phase II rectal microbicide trial. The Microbicide Trial Network's study, called MTN-017, will test a reduced glycerin formulation of tenofovir gel applied rectally. Volunteers consisting of gay men, other men who have sex with men, and transgender women will participate in the study at sites in the United States and in Thailand, South Africa, and Peru.

"Today feels like every holiday imaginable rolled into one," said Jim Pickett, chair of International Rectal Microbicide Advocates (IRMA.) "The launch of the MTN-017 study is a milestone long in the making and marks a giant leap forward in the development of safe, effective, acceptable, and accessible products that could be used to prevent HIV during anal intercourse."

IRMA is pleased to have participated in an intensive community input process with the Microbicide Trials Network that included in-person consultations with advocates and key stakeholders in Thailand, South Africa, Peru and the United States. "The dreams and desires of many men, women, and transgender individuals the world over can be heard loud and clear in the design of the MTN-017 trial. This deep collaboration between scientists and community members is key to the success of this trial and to the rectal microbicide field in general," said Pickett.

Advertisement

When microbicides were first imagined, they were "vagina-centric." While many embraced the notion of creating vaginal products women could control, the majority of the HIV/AIDS community -- scientists and advocates alike -- dismissed the possibility of developing rectal microbicides for use during anal intercourse as an HIV prevention method. It was not considered feasible and the pursuit was seen as hopeless, even laughable. At best, the rectal microbicide field would consist of testing vaginal microbicides for rectal safety, because these products would undoubtedly end up in the rectum despite their intended destination.

IRMA thanks the visionary scientists, advocates and funders like the U.S. National Institutes of Health who bucked prevailing "wisdom" and have remained steadfast in their commitment to developing new HIV prevention methods for use during anal intercourse.

"I feel like we are taking two giant leaps forward today. One in the fight against HIV, and the other in the fight against ignorance and small thinking," said Pickett.

Learn more about the MTN-017 study.

Watch this video: "The Rectal Revolution Is Here: An Introduction to Rectal Microbicide Clinical Trials" in English, Spanish or Thai.



  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary

This article was provided by International Rectal Microbicide Advocates. Visit IRMA's website to find out more about their activities and publications.
 
See Also
More Analysis and Views on Microbicides

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement